Plus Therapeutics (PSTV) Non-Current Deffered Revenue (2010 - 2023)
Plus Therapeutics (PSTV) reported Non-Current Deffered Revenue of $1.9 million for Q4 2023, up 17.1% year-over-year from $1.6 million in Q4 2022, and up 17.1% quarter-over-quarter from $1.6 million in Q4 2022.
Plus Therapeutics (PSTV) Non-Current Deffered Revenue (2010 - 2023) Analysis & Trends
Plus Therapeutics (PSTV) has 12 years of Non-Current Deffered Revenue data on file, last reported at $1.9 million in Q4 2023.
- Non-Current Deffered Revenue for Q4 2023 came in at $1.9 million, up 17.1% year-over-year; the trailing twelve-month figure through Dec 2023 was $1.9 million (up 17.1% YoY), and the FY2023 annual result was $1.9 million, up 17.1% from the prior year.
- Non-Current Deffered Revenue advanced to $1.9 million in Q4 2023 per PSTV's latest filing, from $1.6 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $1.9 million in Q4 2023 and troughed at $142000.0 in Q1 2019.
- A 3-year average of $1.2 million and a median of $1.6 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2019 and 2023: Non-Current Deffered Revenue surged 35.24% in 2019, then gained 17.1% in 2023.
- A 3-year view of Non-Current Deffered Revenue shows it stood at $142000.0 in 2019, then soared by 1057.04% to $1.6 million in 2022, then grew by 17.1% to $1.9 million in 2023.
- Business Quant data shows PSTV's Non-Current Deffered Revenue at $1.9 million in Q4 2023, $1.6 million in Q4 2022, and $142000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Mar 31, 2019 | 142,000.00 |
| Dec 31, 2018 | 167,000.00 |
| Sep 30, 2018 | 83,000.00 |
| Jun 30, 2018 | 93,000.00 |
| Mar 31, 2018 | 105,000.00 |
| Dec 31, 2017 | 107,000.00 |
| Sep 30, 2017 | 120,000.00 |
| Jun 30, 2017 | 136,000.00 |
| Mar 31, 2017 | 17,000.00 |
| Dec 31, 2016 | 17,000.00 |
| Sep 30, 2016 | 41,000.00 |
| Jun 30, 2016 | 111,000.00 |
| Mar 31, 2016 | 189,000.00 |
| Dec 31, 2015 | 269,000.00 |
| Sep 30, 2015 | 348,000.00 |
| Jun 30, 2015 | 419,000.00 |
| Mar 31, 2015 | 507,000.00 |
| Dec 31, 2014 | 558,000.00 |